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ABSTRACT
Objective To highlight the contribution of the gut
microbiota to the modulation of host metabolism by
dietary inulin-type fructans (ITF prebiotics) in obese
women.
Methods A double blind, placebo controlled,
intervention study was performed with 30 obese women
treated with ITF prebiotics (inulin/oligofructose 50/50
mix; n=15) or placebo (maltodextrin; n=15) for
3 months (16 g/day). Blood, faeces and urine sampling,
oral glucose tolerance test, homeostasis model
assessment and impedancemetry were performed before
and after treatment. The gut microbial composition in
faeces was analysed by phylogenetic microarray and
qPCR analysis of 16S rDNA. Plasma and urine metabolic
proﬁles were analysed by 1H-NMR spectroscopy.
Results Treatment with ITF prebiotics, but not the
placebo, led to an increase in Biﬁdobacterium and
Faecalibacterium prausnitzii; both bacteria negatively
correlated with serum lipopolysaccharide levels. ITF
prebiotics also decreased Bacteroides intestinalis,
Bacteroides vulgatus and Propionibacterium, an effect
associated with a slight decrease in fat mass and with
plasma lactate and phosphatidylcholine levels. No clear
treatment clustering could be detected for gut microbial
analysis or plasma and urine metabolomic proﬁle
analyses. However, ITF prebiotics led to subtle changes
in the gut microbiota that may importantly impact on
several key metabolites implicated in obesity and/or
diabetes.
Conclusions ITF prebiotics selectively changed the gut
microbiota composition in obese women, leading to
modest changes in host metabolism, as suggested by
the correlation between some bacterial species and
metabolic endotoxaemia or metabolomic signatures.
INTRODUCTION
Obesity represents a major public health problem,
as it leads to metabolic disorders involved in the
development of type 2 diabetes, fatty liver disease
or cardiovascular disease.1 The gut microbiota is
now considered a key ‘endogenous’ organ contrib-
uting to the modulation of host physiology and
constitutes a plausible target in the control of
obesity and related metabolic disorders.2 3 Indeed,
several studies in rodents (ie, germ-free vs conven-
tionally raised mice) suggest that the gut micro-
biota promotes energy storage by changing host
gene expression.4–6 Moreover, we have proposed
that metabolic endotoxaemia (ie, increased blood
lipopolysaccharide (LPS) levels) triggers low-grade
inﬂammation occurring with overfeeding, obesity
and diabetes,7 and thus contributes to these meta-
bolic disorders.8–11 In humans, obesity is charac-
terised by dysbiosis. Initial studies have shown that
changes in the proportion and/or level of predomin-
ant bacterial phyla (a decrease in Bacteroidetes
and/or an increase in Firmicutes) occur in obese
individuals and may be reversed by dieting and
Signiﬁcance of this study
What is already known on this subject?
▸ Dysbiosis is associated with obesity and related
metabolic disorders.
▸ Dietary inulin-type fructans (ITF) selectively
change the gut microbiota composition and
improve host physiological functions in obese
rodents.
▸ The beneﬁcial effect of ITF (prebiotic effect) in
non-obese humans is often linked to a promo-
tion of biﬁdobacteria in the colon.
What are the new ﬁndings?
▸ ITF prebiotics induce a huge biﬁdogenic effect
but also modify numerous other bacteria in
obese women.
▸ The changes in gut microbiota induced by ITF pre-
biotics are correlated with bacterial-related meta-
bolites (phosphatidylcholine, lactate, hippurate)
and with serum lipopolysaccharide levels, despite
a lack of signiﬁcant effect on body weight.
▸ As inferred from the Human Intestinal Tract Chip
(HITChip) analysis (phylogenetic microarray
based on 16S rRNA gene sequences for the
study of the human gastrointestinal microbiota)
and the metabolomic signatures, the prebiotic
approach selectively changes microbiota-related
host functions.
How might it impact on clinical practice in
the foreseeable future?
▸ ITF prebiotics might be used to support the
dietary advice to control obesity and related
metabolic disorders including diabetes, and car-
diovascular or liver disease. Our results indicate
bacterial types or functions that could constitute
novel therapeutic targets in this major public
health issue.
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weight loss,4 12–14 but these changes remain a matter of
debate.15 16 Speciﬁc changes also occur at the genus level, such
as lower biﬁdobacteria in obese versus lean and diabetic versus
non-diabetic individuals.15 17
The concept of prebiotic is based on the possibility of favour-
ably modulating the gut microbiota composition to maintain
and/or promote health, using nutrients such as non-digestible,
fermentable carbohydrates.18 19 Among these, inulin-type fruc-
tans (ITF) have been proposed as modulators of microbial
ecology and host physiology in animals and humans.3 20 In
diet-induced or genetic models of obesity in rodents, ITF were
shown to decrease body weight gain and fat mass accumulation,
improve glucose tolerance and insulin resistance, decrease
inﬂammation and improve gut barrier function.9 21–23 Moreover,
in these animal models, ITF modulated gut microbiota compos-
ition leading mainly to a biﬁdogenic effect.23 24 Recently,
an extensive analysis of the gut microbiota composition after
feeding obese mice short-chain ITF revealed that prebiotic treat-
ment decreased Firmicutes and increased Bacteroidetes, and
changed more than 100 taxa of bacteria. This was associated
with beneﬁcial effects on host metabolism, such as an improve-
ment in glucose and lipid metabolism and a reduction of
plasma LPS.25
Some of these effects have also been observed in humans.
We, and others, have demonstrated that in healthy humans,
short-chain ITF promoted satiety,26 27 increased breath-
hydrogen excretion (a marker of gut microbiota fermentation)
and modulated gut peptides regulating food intake.27 28 In over-
weight and obese adults, short-chain ITF supplementation pro-
moted weight loss, improved glucose regulation and modulated
the production of peptides implicated in energy intake.29 The
aim of our exploratory study was to evaluate the impact of ITF
prebiotics on the gut microbial ecosystem in obese women
to highlight the contribution of gut microbial changes in the
modulation of host metabolism on nutritional intervention.
A metabolomic analysis in urine and plasma was also performed
in parallel to evaluate the potential interest of microbial-related
metabolites as novel biomarkers of prebiotic intervention.
METHODS
Subjects
Forty-four obese women (body mass index (BMI) >30 kg/m2)
between the ages of 18 and 65 years were voluntarily recruited
from the Cliniques Universitaires Saint Luc, Brussels, Belgium
between March 2008 and May 2011. Eight patients failed to
complete the study for the following reasons: pregnancy (one
patient), loss of phone contact during follow-up (one patient),
gastro-oesophageal reﬂux (two patients), personal reasons (two
patients) and absence of weight loss (two patients). Of the 36
patients who completed the study, three patients per group
were excluded from the analysis because of antibiotic treatment
during the study and inadequate or missing faecal sampling.
Finally, 15 patients per group were included in the analysis
(ﬁgure 1). The subjects were assigned to the ITF or placebo
group following a systematic allocation method. The exclusion
criteria were: presence of gastrointestinal disorders or a history
of chronic physical/mental disease, use of antidiabetic drugs or
weight-loss treatments, recent consumption (<6 weeks) of
antibiotics or treatments that inﬂuence gut microbiota compos-
ition, chronic consumption of antacids or anti-inﬂammatory
drugs, pregnancy, unusual diets (vegetarians, vegans and high
consumption of dietary supplements), consumption of pre/
probiotics or ﬁbre supplements, excessive alcohol consumption
(>30 glasses of alcoholic beverages/week), intensive physical
training, a history of bariatric surgery, and gastro-oesophageal
reﬂux treated with high doses of proton pump inhibitors. The
Commission d’Ethique Biomédicale Hospitalo-facultaire from
the Université catholique de Louvain (Brussels, Belgium)
provided ethical approval for this study and written informed
consent was obtained from each participant. The trial was
registered at clinicaltrials.gov as NCT00616057.
Dietary intervention
The subjects were assigned to receive either a daily supplement
of 16 g (8 g twice a day) of ITF (Synergy 1, namely, inulin/
oligofructose 50/50 mix) or placebo (maltodextrin) for 3 months
(both products were kindly provided by Orafti, Oreye, Belgium).
Maltodextrin has a taste and appearance similar to Synergy 1
and has been used as a placebo for ITF in previous studies.26–29
The patients were asked to take a half dose during the ﬁrst week
of treatment to promote adaptation to the ﬁbre and reduce
gastrointestinal symptoms. Both the placebo and ITF were pro-
vided in identical opaque packages (named A or B and distribu-
ted as follows: patient 1/A, patient 2/B, patient 3/A, patient
4/B,…). The powder was added in warm drinks such as coffee,
tea or hot chocolate or in dairy products. The subjects and the
researchers were blinded to the treatment.
Figure 1 Trial proﬁle. Of the 44
enrolled patients, eight patients failed
to complete the study for the following
reasons: pregnancy (one patient), loss
of contact during follow-up (one
patient), gastro-oesophageal reﬂux
(two patients), personal reasons (two
patients) and absence of weight loss
(two patients). Of the 36 patients who
completed the study, three patients per
group were excluded from the analysis
because of antibiotic treatment during
the study and inadequate or missing
faecal sampling.
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Trial protocol
After verifying that the patients met the inclusion criteria and
obtaining consent, the patients were submitted to an anam-
nesis and received dietary advice for weight loss. At the begin-
ning (T0) and the end of the treatment (T3 months), blood,
faeces and urine were sampled. Blood was collected in EDTA
tubes and a portion was sent directly to the hospital laboratory
to measure the following classical biological parameters: gly-
caemia, insulinaemia, HbA1c, aspartate transaminase, alanine
transaminase, alkaline phosphatase, C-reactive protein (CRP),
total cholesterol, high-density and low-density lipoproteins
(HDL and LDL, respectively) cholesterol and triglycerides. The
remainder of the blood was centrifuged at 4200 g for 10 min at
4°C and the plasma was frozen at −80°C. Adiponectinaemia
was determined using the RayBio ELISA kit (RayBiotech,
Norcross, Georgia, USA). Faeces and urine samples were frozen
at −20°C. Patients were also submitted to an oral glucose toler-
ance test (OGTT) (75 g glucose in drinking solution and meas-
urement of glycaemia and insulinaemia 2 h after ingestion) and
to a homeostasis model assessment (HOMA) test. HOMA esti-
mates insulin sensitivity from the fasting glucose and insulin
concentrations.30 Finally, weight and body composition were
determined by impedancemetry (Tanita BC-418MA, Tanita UK,
West Drayton, UK). The BMI was calculated and waist and hip
circumferences were measured. A telephone follow-up was per-
formed three times during the study (after 2 weeks, 1 month
and 2 months of treatment) to verify compliance and enquire
about possible side effects.
The primary endpoint of this study was to assess the pre-
biotic effect of ITF on gut microbiota composition in obese
women. We focused on the biﬁdogenic effect because several
studies with ITF in healthy humans had highlighted a signiﬁ-
cant increase in biﬁdobacteria following the prebiotic treat-
ment.24 31 Patient enrolment was stopped when the primary
endpoint, namely a statistically signiﬁcant increase in faecal
biﬁdobacteria quantiﬁed by qPCR in the ITF group, was
effective (ie, 15 patients/group). The effect of ITF on clinical
outcome and metabolic proﬁling was then evaluated as a
secondary aim.
Gut microbiota analysis
Faecal samples were collected and stored at −20°C until further
processing. The DNA was isolated as previously described,32
using the repeated bead beating procedure with a modiﬁed
protocol for the QiAamp Stool DNA Mini Kit (Qiagen, Hilden,
Germany). Faecal microbiota composition was assessed using
qPCR (see online supplemental methods) and the Human
Intestinal Tract Chip (HITChip), a phylogenetic microarray.33
The HITChip contains over 4800 probes based on 16S rRNA
gene sequences of over 1100 intestinal bacterial phylotypes and
identiﬁes both variation and relative quantity of the human
intestinal tract communities.34 Hybridisations were performed
with samples labelled in duplicate with Cy3 and Cy5 dyes.
Slides data were extracted from the microarray images using
Agilent Feature Extraction software, V.10.7.3.1 (http://www.
agilent.com). Array normalisation was performed as previously
described,34 35 with a set of R-based scripts (http://r-project.org)
in combination with a designed relational database which runs
under the MySQL database management system (http://www.
mysql.com). This procedure was applied on both dyes for each
sample, and duplicates with a Pearson correlation over 0.98 were
considered for further analysis. Ward’s minimum variance
method was used for the construction of hierarchical clusters of
the total microbiota probe proﬁles, while the distance matrix
between the samples was based on Pearson correlations.
Metabolic proﬁling by 1H NMR spectroscopy
400 ml of the urine samples was mixed with 200 μl of phos-
phate buffer (0.2M, pH 7.4) made in D2O containing 0.01%
deuterated 3-(trimethysilyl)-1-propanesulfonic acid and 3 mM
sodium azide. 200 ml of the plasma samples was mixed with
400 μl of D2O. Samples were centrifuged 10 min at 4°C
(8000 g) and transferred to 5 mm tubes for nuclear magnetic
resonance (NMR) analysis.
All 1H NMR spectra were acquired on a Bruker Avance
700 MHz spectrometer (Bruker Analytische, Rheinstetten,
Germany) operating at 700.19 MHz and equipped with a 5 mm
CryoProbe from the same manufacturer. See online supplemen-
tal methods for details.
Serum LPS measurement
LPS concentrations were measured by using Endosafe-MCS
(Charles River Laboratories, Lyon, France) based on the Limulus
Amoebocyte Lysate kinetic chromogenic methodology, as previ-
ously described.36 Samples were diluted from 1/30 to 1/100.
Statistical analyses
Raw data are expressed as mean±SD. Treatment effect was
assessed based on differential values obtained by subtracting
the value at T0 from the value at T3 months for each patient.
Differential values are expressed as mean±95% CI. As most of
the parameters had an abnormal distribution (assessed using
a Shapiro–Wilk test), the Mann–Whitney test was used to
compare differential values or both groups at T0. Correlations
were analysed by using Spearman’s correlation in GraphPad
Prism (V.5.00 for Windows, GraphPad Software, San Diego,
California, USA). The level of signiﬁcance was set at p<0.05.
For the HITChip analysis, the Wilcoxon signed-rank test cor-
rected for false discovery rate,37 was applied to evaluate the sig-
niﬁcant differences of individual genus-level groups in the
microbiota of both groups after 3 months. For comprehensive
multivariate statistical analyses, Canoco software for Windows
4.5 was used.38 Redundancy analysis was used to assess correla-
tions between the microbial groups detected by the HITChip ana-
lysis in the function of sample characteristics. This redundancy
analysis is a multivariate analysis that shows the distribution of
the samples in a three-dimensional space based on species vari-
ables and environmental variables. The log transformed hybrid-
isation signals of 131 genus-level phylogenetic groups targeted by
the HITChip were used as species variables. As environmental
variables, we included age, BMI, gender, antibiotic use, sample
collection time and sample source (placebo or prebiotic group at
T0 and T3 months). The Monte Carlo Permutation Procedure as
implemented in the Canoco software package was used to assess
statistical signiﬁcance of the variation in large datasets.
Statistical analyses for metabolic proﬁling are described in
the online supplemental methods.
RESULTS
As described in the Methods section, 15 patients per group
were included in the analysis (except for the HITChip analysis,
in which we excluded one outlier sample in the treated group).
Minor side effects were reported at the beginning of the treat-
ment: six patients in the placebo group and 14 patients in the
treated group had slight bloating, ﬂatulence and/or abdominal
pain. Those symptoms disappeared within a few days in most
patients.
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The baseline characteristics of the patients are reported
in table 1. There were no differences between the two groups
at the beginning of the study.
Analysis of the gut microbiota composition
The HITChip analysis revealed an important modulation of
the gut microbiota composition in patients treated with ITF
prebiotics for 3 months. These changes occurred at the phylum
level (subdivided for the Firmicutes over classes and Clostridium
clusters) and the genus-like taxonomic level with phylotypes
with >90% 16S rRNA gene sequence similarity (see online
table S1). ITF prebiotics induced a signiﬁcant increase in
Firmicutes and Actinobacteria and a decrease in Bacteroidetes
(ﬁgure 2A). Changes in Firmicutes were due to a signiﬁcant
increase of three groups belonging to this phylum, namely
the bacilli, and Clostridium clusters IV and XVI (the bacterial
groups belonging to these three classes are described in online
table S2). At the genus-like taxonomic level (ﬁgure 2B), an
increase in Biﬁdobacterium and Faecalibacterium prausnitzii and a
decrease in Bacteroides intestinalis and B vulgatus occurred after
Table 1 Descriptive characteristics at the beginning of treatment for
all subjects included in the data analysis; n=15 for each group
Placebo (n=15) Prebiotic (n=15)
Age (years) 48±8 47±9
Body weight (kg) 97.5±15.8 99.1±16.3
Body mass index (kg/m2) 35.6±4.3 36.1±4.1
Fat mass (%) 46.1±3.9 45.4±3.5
Waist circumference (cm) 114.3±11.8 115.6±11.9
HbA1c (%) 5.8±0.5 5.6±0.5
Fasting glycaemia (mg/dl) 99±15 97±18
Results are given as mean±SD.
Figure 2 Human Intestinal Tract Chip analysis. (A) Relative contribution (mean percentage of total detected bacteria at the phylum level) of the
major phyla in both groups (placebo and treated): (1) before; and (2) after treatment. *p<0.05 according to the Wilcoxon signed rank test (T0 vs
T3 months in the prebiotic group). Exact p values are given in online supplemental table S1. (B) Relative contribution (mean percentage of total
detected bacteria at the genus-like taxonomic level) of the species/genus of bacteria in both groups before and after treatment (Preb-1: prebiotic
group, T0; Preb-2: prebiotic group, T3 months; Plac-1: placebo group, T0; Plac-2: placebo group, T3 months).
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ITF prebiotic treatment but not after placebo treatment. The
important increase in biﬁdobacteria following prebiotic treat-
ment was conﬁrmed by qPCR (ﬁgure 3A). The HITChip ana-
lysis also revealed an important change for Lactobacillus gasseri
(a 34.4-fold change), occurring mainly in three patients belong-
ing to the prebiotic group. Lactobacilli analysis by qPCR high-
lighted a signiﬁcant effect of the prebiotic treatment on the
genus Lactobacillus spp. with an increase in the prebiotic group
and no change in the placebo group (ﬁgure 3B).
A hierarchical clustering of the HITChip data did not reveal
any clustering between the patients of each group but con-
ﬁrmed the important inter-individual variations with clusters
observed between samples coming from the same patient (see
online ﬁgure S1).
To assess for differences in microbiota composition of both
groups at T0 and T3 months, a multivariate statistics approach
was used. A redundancy analysis showed that, although the
different study groups did not change signiﬁcantly in com-
position, the samples belonging to the prebiotic group at
3 months positively correlated with Actinobacteria (including
the Biﬁdobacterium group) and negatively correlated with
Bacteroidetes and Proteobacteria (see online ﬁgure S2).
Anthropometric and blood parameters
After 3 months of treatment, ITF prebiotics had no signiﬁcant
impact on BMI and waist/hip ratio but tended to decrease fat
mass even if the differential values were not signiﬁcantly differ-
ent between both groups (ﬁgure 4A).
The prebiotic treatment did not signiﬁcantly modify HbA1c,
fasting glycaemia and insulinaemia, post-OGTT insulinaemia,
HOMA index or adiponectinaemia. However, we observed a
signiﬁcant difference in the post-OGTT glycaemia, with an
increase occurring in the placebo group and a slight decrease
observed in the treated group. The prebiotic treatment had no
signiﬁcant effect on cholesterol (total, HDL or LDL) and trigly-
cerides (see online table S3).
Finally, treatment effect on plasma CRP was not signiﬁcant.
Metabolic endotoxaemia was decreased in both groups but to a
higher extent in the prebiotic group, even if the treatment
effect did not reach signiﬁcance (ﬁgure 4B).
Correlations between gut bacteria and biological parameters
A Spearman correlation analysis was performed to evaluate the
potential link between signiﬁcant changes in gut microbiota
composition induced by prebiotics and host metabolism
(ﬁgure 5). LPS changes signiﬁcantly and negatively correlated
with several phyla and species of bacteria that were increased
by the prebiotics, namely Firmicutes (bacilli appear to be
responsible for this correlation), Actinobacteria, Biﬁdobacterium
and Faecalibacterium prausnitzii. Changes in Clostridium cluster
IV group (which was also increased by ITF) negatively corre-
lated with anthropometric parameters and with the fasting gly-
caemia, insulinaemia and HOMA index. In contrast, changes in
Propionibacterium, Bacteroides intestinalis and Bacteroides vulgatus,
all three being signiﬁcantly decreased by prebiotic treatment,
positively correlated with changes in body composition and
glucose homeostasis.
Metabolic proﬁling by 1H NMR spectroscopy
Overall, the multivariate statistical analysis of urine and plasma
NMR spectra did not allow separating the metabolic proﬁles
observed in the placebo and treated groups at either time point
(data not shown). Nevertheless, in plasma, we observed a signiﬁ-
cant, positive correlation between the partial least square (PLS)
scores of the NMR spectra and Propionibacterium and Bacteroides
vulgatus (ﬁgure 6A). The discriminant metabolites explaining
this correlation were lactate and phosphatidylcholine (PC),
meaning that these two metabolites were increased in patients
where Propionibacterium and Bacteroides vulgatus were more
abundant (ﬁgure 6B shows the PLS loading plot for
Propionibacterium).
The PLS scores of the urine NMR spectra signiﬁcantly corre-
lated with the waist/hip ratio and with the post-OGTT insulin
(see online ﬁgure S3). The PLS loadings of these two models
showed that creatinine and hippurate negatively correlated
with post-OGTT insulin, whereas creatinine alone correlated
with the waist/hip ratio. Finally, changes in the levels of
Collinsella, a bacterial genus signiﬁcantly increased by prebiotic
treatment, signiﬁcantly correlated with the PLS scores of
urinary metabolic proﬁles (ﬁgure 6C). Hippurate was associated
with these changes in Collinsella as depicted by the PLS
Figure 3 Gut microbiota analysis by quantitative PCR. (A) Biﬁdobacterium spp.; (B) Lactobacillus spp. Left: individual levels in log (CFU/g faeces)
for each patient of the placebo and prebiotic groups before (T0) and after (T3 months) treatment. Right: differential values (T3 months–T0) in log
(CFU/g faeces). Results are given as mean±95% CI. p Values according the Mann-Whitney test (placebo vs prebiotic) to assess treatment effect.
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loadings. The PLS parameters of the listed models are given in
the online supplemental methods.
DISCUSSION
Over the past few years, interest has grown regarding the
potential role of the gut microbiota in the occurrence of
obesity and related diseases. Nutritional approaches are consid-
ered potential tools to modulate the gut microbiota with a con-
comitant impact on health.2 3 We show, for the ﬁrst time, that
a 3-month treatment with ITF prebiotics led to a selective
modulation of the gut microbiota composition in obese
women. At the phylum level, the ITF treatment increased
Firmicutes and Actinobacteria and decreased Bacteroidetes.
This result was intriguing because other studies observed an
increased Firmicutes and/or a decreased Bacteroidetes count in
obese versus lean individuals. These changes could be inverted
after a diet-induced weight loss and were division-wide with no
speciﬁc subgroup being preferentially decreased or
increased.4 13 39 In our study, increased levels of Firmicutes fol-
lowing prebiotic treatment were due to increases in bacilli, and
Clostridium clusters IV and XVI. Interestingly, changes in bacilli
were negatively associated with changes in LPS, whereas
changes in Clostridium cluster IV negatively correlated with
changes in fat mass and fasting glucose homeostasis. This
observation suggests a positive impact of the prebiotics on
these speciﬁc Firmicutes. Consistent with this, Schwiertz et al
recently showed a higher level of the Clostridium leptum group,
Faecalibacterium prausnitzii being the major bacterium of this
group, in lean patients compared to obese individuals.15
In addition, other studies have shown similar levels of
Bacteroidetes in lean and obese individuals,16 or even an
increased proportion of this phylum in overweight and obese
patients,15 thus showing that the potential change of
Bacteroidetes in obesity is controversial. Moreover, Wu et al
recently studied the impact of diet on gut microbiome using
diet inventories and 16S rDNA sequencing to characterise
faecal samples from 98 individuals.40 They observed that bac-
terial phyla were related to diet, with Bacteroidetes being posi-
tively associated with fat and negatively associated with ﬁbre,
and Firmicutes showing an opposite correlation. Interestingly,
these associations were in accord with the results obtained
with ITF prebiotics, which are fermentable dietary ﬁbres.
Among the prebiotic-induced speciﬁc changes at the genus-
like taxonomic level, signiﬁcant increases in Biﬁdobacterium
and Faecalibacterium prausnitzii were of particular interest.
Biﬁdobacteria have been shown to decrease in obesity and dia-
betes,7 15 17 41 and to increase on prebiotic treatment, leading
to improved host metabolism in rodents and healthy
humans.23 24 31 42 43 F prausnitzii is depleted in inﬂammatory
bowel disease (IBD) and Crohn’s disease patients and exhibits
Figure 4 (A) Anthropometric characteristics. (B) Plasma C-reactive protein (CRP) and serum lipopolysaccharide (LPS) of patients in both groups
(placebo and treated) before (T0) and after (T3 months) treatment. Differential values (T3 months–T0) are given as mean±95% CI. Statistical
analysis performed on transformed values (log) for LPS. BMI, body mass index.
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anti-inﬂammatory effects in vitro (cellular models) and in vivo
(TNBS-induced colitis in mice).44–46 It is also decreased in
obese diabetic patients compared to non-diabetic individuals
(lean and obese) and tends to increase after bariatric surgery.
Furthermore, it is negatively correlated with inﬂammatory
markers in obese patients both before and after bariatric
surgery.47 In healthy humans, ITF prebiotics signiﬁcantly
increase the levels of F prausnitzii.31 In our study, prebiotic-
induced changes in Biﬁdobacterium and F prausnitzii negatively
correlated with changes in LPS, a pro-inﬂammatory compo-
nent. This result is of particular interest in view of the central
role played by metabolic endotoxaemia in the process of low-
grade inﬂammation in obesity.7 8 23
At the beginning of the treatment, there was no statistical dif-
ference in anthropometric and blood parameters between both
groups of patients. Although ITF prebiotics showed promising
results on gut microbiota composition in obese women, they did
not signiﬁcantly impact BMI, lipid or glucose homeostasis but
they tended to decrease fat mass. We cannot exclude that ten-
dencies observed for the clinical parameters could have become
signiﬁcant with a higher number of patients.
Nevertheless, the metabolic proﬁling of urine and plasma
revealed interesting correlations between metabolites implicated
in obesity and some gut bacteria. Levels of Propionibacterium
and Bacteroides vulgatus, both decreased by prebiotic treatment,
positively correlated with plasma levels of PC and lactate.
Propionibacterium is a bacterial genus with probiotic properties,
mainly isolated from dairy products.48 A Mouse Intestinal
Tract Chip analysis has revealed a signiﬁcant increase of this
genus in db/db mice compared to lean mice (Cani PD, personal
communication). Bacteroides vulgatus has been found to consti-
tute part of the core gut microbiota in healthy humans and is
generally considered beneﬁcial.49–51 However, it has also been
associated with a higher genetic risk of developing coeliac
disease and some speciﬁc strains of B vulgatus are capable of
promoting colitis,52 53 thus suggesting a controversial impact
on health. Dumas et al have demonstrated that mice developing
insulin resistance and non-alcoholic fatty liver disease have
lower levels of PC, leading to an impairment of very low
density lipoprotein secretion and, thereby, hepatic triglycerides
accumulation.54 Nevertheless, other studies have shown
that PC levels are higher in obesity and decrease following
diet-induced weight loss or bariatric surgery.55 56 Moreover, PC
molecules are increased in conventionally raised (CONV-R)
animals compared to germ-free mice, which have lower adipos-
ity and hepatic triglycerides than their CONV-R counter-
parts.57 Disturbances in whole body lactate turnover appear to
contribute to the development of insulin resistance. Elevated
plasma levels of lactate have been reported in both obesity and
type 2 diabetes.58–60
Thus, low levels of plasma PC and lactate, which were
observed in patients with low levels of Propionibacterium and
Bacteroides vulgatus in the prebiotic group, appeared to be asso-
ciated with lower adiposity. Moreover, changes in these bacteria
positively correlated with changes in fat mass and glucose
homeostasis. This correlation was in accord with the higher
levels of Propionibacterium in diabetic db/db mice, thus conﬁrm-
ing their potential negative role on host metabolism, at least in
pathological situations linked to glucose homeostasis distur-
bances (Cani PD, personal communication).
Finally, increased levels of Collinsella, a genus belonging to
Actinobacteria and signiﬁcantly augmented with prebiotics,
correlated with higher urinary levels of hippurate. Collinsella
aerofaciens has been associated with a low risk of colon cancer,61
Figure 5 Heat map of the Spearman r correlations between the gut bacteria signiﬁcantly modiﬁed by the prebiotic treatment and anthropometric/
biological parameters. Correlations were performed on differential values (T3 months–T0) for each patient in both groups (placebo and treated).
*p<0.05; $p<0.1 following the Spearman correlation. ALT, alanine transaminase; AST, aspartate transaminase; BMI, body mass index; CRP,
C-reactive protein; FM, fat mass; HDL, high-density lipoprotein; HOMA, homeostasis model assessment; LDL, low-density lipoprotein; LM, lean
mass; LPS, lipopolysaccharides; OGTT, oral glucose tolerance test; TG, triglycerides.
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and patients with IBD present lower gut levels of this genus than
do control individuals.62 Hippurate is a gut-derived metabolite
commonly associated with a ‘healthy phenotype’. It is decreased
in diabetes and obesity and increases following bariatric surgery.
Moreover, it is one of the main discriminant metabolites explain-
ing the difference in urine metabolic proﬁles between lean and
obese or diabetic individuals.63–65 Thus, increased levels of
Collinsella and urinary hippurate could be considered as a beneﬁ-
cial effect associated with ITF fermentation.
In conclusion, the prebiotic intervention was not sufﬁcient
to induce signiﬁcant clustering in the overall metabolomic or
gut microbiota proﬁles between the two groups of patients.
However, we discovered subtle changes in the gut microbiota
which correlated with changes in fat mass, serum LPS levels
and metabolism (hippurate, lactate and PC). Thus, by model-
ling symbiotic biology systems (eg, the gut microbiota–host
interactions) with prebiotics in obese women, we identiﬁed
potential supersystem interactions associated with the occur-
rence of obesity and related diseases. Accordingly, our study
may be considered as a prerequisite to better deﬁne the target
population and patient characteristics for further larger inter-
vention studies.
Figure 6 (A) Partial least square (PLS) regression analysis between plasma metabolic proﬁles and gut levels of Propionibacterium and Bacteroides
vulgatus: score plots showing the correlation between bacterial levels (relative contribution: y axis) and PLS scores (x axis). (B) PLS loading plot for
Propionibacterium showing the contribution of plasma lactate and phosphatidylcholine to the model. (C) PLS regression analysis between changes in
urinary metabolic proﬁles and changes in the gut levels of Collinsella performed on differential values (T3 months–T0). Left: PLS scores (x axis) are
plotted against Collinsella levels (relative contribution: y axis). Right: PLS loading plot showing the contribution of hippurate to the model. Details of
model parameters are described in the online supplemental methods section.
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